Celularity vs Cytomx Therapeutics
Cytomx Therapeutics is the larger business, with $76.2m of revenue in fiscal 2025 against $26.6m for Celularity (2.9 times as much). Cytomx Therapeutics grew faster (-44.8% against -51.0%). Cytomx Therapeutics kept more of each dollar of sales as profit: a net margin of -22.8% against -345.4%.
| Latest fiscal year | CelularityCELU, 2025 | Cytomx TherapeuticsCTMX, 2025 |
|---|---|---|
| Revenue | $26.6m | $76.2m |
| Revenue growth | -51.0% | -44.8% |
| Net income | −$91.7m | −$17.4m |
| Operating margin | -230.9% | -29.3% |
| Net margin | -345.4% | -22.8% |
| Return on equity | — | -35.2% |
| Free cash flow | −$13.3m | −$75.8m |
| Cash | $6.2m | $12.7m |
| Total debt | $33.8m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 115 | 69 |
| Market value | $23.5m | $380m |
| Price vs our value range | — | — |
| Moat score | 18 (Weak) | 9 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 7 sales |